

Please try another search
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
Name | Age | Since | Title |
---|---|---|---|
John W. Varian | 65 | 2017 | Independent Chairman of Board |
David A. Scheinberg | 69 | 2015 | Independent Director |
Jane Wasman | 69 | 2017 | Independent Director |
Javier Pinilla-Ibarz | - | 2016 | Member of Scientific Advisory Board |
Robert L. Van Nostrand | 68 | 2017 | Independent Director |
Angelos M. Stergiou | 49 | 2012 | Founder, President, CEO & Director |
Larry W. Kwak | - | 2015 | Member of Scientific Advisory Board |
Guenther Koehne | - | - | Member of Scientific Advisory Board |
Katherine Bach Kalin | 62 | 2022 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review